[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure-with-mildly-reduced-ejection-fraction-hfmref\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure-with-mildly-reduced-ejection-fraction-hfmref":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100651424","phase-3-a-study-to-investigate-cv-outcomes-with-elecoglipron-compared-with-placebo-in-adult-participants-with-hfpef-or-hfmref-100651424",false,"NCT07761117","A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF","A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)","Elevate-HF","Inclusion Criteria:\n\n* Left ventricular ejection fraction (LVEF) of \\> 40% within 12 months prior to screening.\n* Structural heart disease evidence.\n* HF diagnosed with New York Heart Association (NYHA) Class II-IV at the time of screening.\n\nExclusion Criteria:\n\n* BMI \\\u003C25 kg\u002Fm² at screening.\n* Diabetes exclusions:\n* History of type 1 diabetes.\n* HbA1c ≥10% at screening.\n* Currently receiving or anticipated to receive therapeutic intervention for diabetic retinopathy and\u002For macular edema.\n* more than 1 episode of severe hypoglycemic event within 180 days prior to screening, or hypoglycemia unawareness\u002Fpoor recognition.\n* Renal exclusions:\n* On a prespecified renal replacement therapy, or eGFR below a prespecified threshold at screening\n* Cardiovascular exclusions:\n* Major cardiac surgery, coronary revascularization, valvular repair\u002Freplacement, AF\u002FAFL ablation, CRT implantation, or ICD without CRT within 90 days prior to screening, or planned after randomization.\n* Heart failure due to infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, genetic hypertrophic cardiomyopathy (including obstructive), or arrhythmogenic right ventricular cardiomyopathy\u002Fdysplasia.\n* GI exclusions:\n* Clinically significant upper GI condition affecting gastric emptying, drug absorption, or safety\u002Ftolerability interpretation; chronic use of drugs directly affecting GI motility; severe disease or prior surgery.\n* History of acute or chronic pancreatitis.\n* Endocrine exclusions:\n* History\u002F family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2, or basal calcitonin ≥35 ng\u002FL at screening.","ALL","18 Years",{"count":20,"type":21},6950,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)\u002Fheart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.",[27,28],"Heart Failure With Preserved Ejection Fraction (HFpEF)","Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)",[30,31],"Heart failure","Elecoglipron","NOT_YET_RECRUITING","2026-08-07",{"date":35,"type":36},"2026-08-12","ACTUAL",{"date":38,"type":21},"2026-08-28",{"date":40,"type":21},"2029-09-03",{"name":42,"class":43},"AstraZeneca","INDUSTRY",366,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100647335","an-ai-ecg-based-approach-for-dynamic-assessment-of-heart-failure-risk-and-myocardial-recovery-following-atrial-fibrillation-ablation-100647335","NCT07708818","An AI-ECG-Based Approach for Dynamic Assessment of Heart Failure Risk and Myocardial Recovery Following Atrial Fibrillation Ablation","DYNAMIC-AF HF Study: An AI-ECG-Based Approach for Dynamic Assessment of Heart Failure Risk and Myocardial Recovery Following Atrial Fibrillation Ablation","Inclusion Criteria:\n\n* Age ≥18 years\n* Symptomatic paroxysmal or persistent atrial fibrillation\n* Scheduled for first-time catheter ablation\n* Left ventricular ejection fraction between 41% and 49% measured by transthoracic echocardiography within 3 months before ablation\n* At least one analyzable sinus rhythm 12-lead electrocardiogram before ablation\n* At least one latent heart failure substrate feature:\n\n  * Elevated NT-proBNP\n  * Increased left atrial volume index (\\>34 mL\u002Fm²)\n  * Average E\u002Fe' ≥14\n  * Reduced global longitudinal strain\n  * Mild pulmonary hypertension\n  * Exertional intolerance suggestive of early heart failure\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction ≤40%\n* Previous atrial fibrillation catheter ablation\n* Significant valvular heart disease requiring intervention\n* Hypertrophic or infiltrative cardiomyopathy\n* Acute coronary syndrome, coronary revascularization, or myocarditis within 3 months\n* Severe renal dysfunction requiring dialysis\n* Active malignancy with life expectancy \\\u003C1 year\n* Inadequate electrocardiographic or echocardiographic image quality\n* Pregnancy\n* Inability or unwillingness to provide written informed consent",true,{"count":54,"type":21},1000,"OBSERVATIONAL","Background Artificial intelligence-enabled electrocardiography (AI-ECG) has emerged as a promising digital biomarker for detecting latent myocardial dysfunction and predicting cardiovascular risk. However, whether serial AI-derived risk estimates reflect myocardial recovery following therapeutic intervention remains unknown.\n\nObjective The DYNAMIC-AF HF Study aims to evaluate longitudinal changes in AI-ECG-derived heart failure (HF) risk after catheter ablation in patients with atrial fibrillation (AF) and heart failure with mildly reduced ejection fraction (HFmrEF), and to determine their association with conventional markers of reverse remodeling.\n\nMethods The DYNAMIC-AF HF Study is a prospective multicenter observational cohort study enrolling 1,000 patients with symptomatic AF and HFmrEF undergoing first-time catheter ablation. Eligible participants must have a left ventricular ejection fraction of 41-49% and at least one predefined HF-related feature suggestive of latent myocardial dysfunction. Serial 12-lead electrocardiograms, echocardiography, biomarker assessments, and clinical follow-up will be performed at baseline and at 3, 6, and 12 months. AI-based ECG analysis will generate continuous HF-risk scores, enabling construction of longitudinal AI-derived HF risk trajectories. The primary endpoint is the change in AI-derived HF risk from baseline to 12 months. Secondary endpoints include changes in left ventricular ejection fraction, global longitudinal strain, N-terminal pro-B-type natriuretic peptide levels, AF recurrence, HF hospitalization, and mortality.\n\nConclusions This study will evaluate whether serial AI-ECG assessment can serve as a dynamic digital biomarker of myocardial recovery following AF ablation and support future AI-enabled monitoring and clinical decision-support strategies in cardiovascular care.",[58,28],"Atrial Fibrillation (AF)",[60,61,62,63,64,65],"artificial intelligence","electrocardiography","digital biomarker","heart failure with mildly reduced ejection fraction","atrial fibrillation","catheter ablation","2026-07-16",{"date":68,"type":36},"2026-07-20",{"date":70,"type":21},"2027-01-01",{"date":72,"type":21},"2029-12-31",{"name":74,"class":75},"Ewha Womans University Mokdong Hospital","OTHER",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":87,"studyType":55,"phases":4,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":76},"100620243","precision-subtyping-and-prognostic-study-of-heart-failure-based-on-multi-omics-integration-and-clinical-indicators-a-prospective-single-center-cohort-study-100620243","NCT07355088","Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study","HF-MultiOmics","Inclusion Criteria:(1)For chronic heart failure (CHF) patients:1.Meet the 2022 European Society of Cardiology (ESC) diagnostic criteria for CHF, classified into heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF) per ESC guidelines;2.Aged 18 to 80 years (inclusive);3.Able to provide written informed consent independently (or via a legal guardian if cognitively impaired, with a Mini-Mental State Examination \\[MMSE\\] score ≥ 24).\n\n(2)For healthy controls:1.No history of cardiovascular disease, confirmed by medical history review and baseline echocardiography;2.Aged 18 to 80 years (inclusive), matched 1:2 with CHF patients by age and gender;3.Able to provide written informed consent.\n\nExclusion Criteria:(1)Acute decompensated heart failure (admitted for acute HF exacerbation within 72 hours prior to enrollment);(2)End-stage renal disease, defined as an estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73m² (confirmed by serum creatinine testing);(3)Active malignancies (receiving systemic treatment within 6 months prior to enrollment) or severe systemic diseases (e.g., severe liver failure, active autoimmune diseases);(4)Antibiotic use within 2 weeks prior to enrollment (may interfere with gut microbiome analysis);(5)Inability to complete 12-month follow-up (e.g., planned long-term overseas residence) or provide required biological samples (e.g., venous blood, fecal samples).","80 Years",{"count":86,"type":21},600,"12 Months","This is a prospective single-center cohort study conducted at The First Affiliated Hospital of Xinjiang Medical University, aiming to enroll 400 patients with chronic heart failure (including HFrEF, HFmrEF, HFpEF) and 200 healthy controls.We will collect clinical data (e.g., NYHA class, NT-proBNP), multi-omics samples (genome, proteome, metabolome, gut microbiome), and imaging indicators (e.g., EAT density, myocardial strain) from participants at baseline. For patients treated with SGLT2 inhibitors, we will also track dynamic changes in multi-omics during follow-up.The main purpose is to build a composite risk prediction model (integrating multi-omics and clinical indicators) to predict the 1-year composite endpoint (heart failure rehospitalization or all-cause death). Secondary goals include identifying specific molecular profiles related to heart failure phenotypes, exploring the \"gut-heart axis\" mechanism, and finding early biomarkers for SGLT2 inhibitor response.All participants will be followed up for at least 12 months, and the study will strictly comply with ethical norms and protect the privacy of participants.",[90,91,92,28],"Chronic Heart Failure","Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Failure With Preserved Ejection Fraction (HFPEF)",[90,94,95,96,97,98,99],"Multi-omics","Gut-heart axis","SGLT2 inhibitors","Risk prediction model","Epicardial Adipose Tissue","Myocardial Strain","2026-01-12",{"date":102,"type":36},"2026-01-21",{"date":104,"type":21},"2026-01-01",{"date":106,"type":21},"2028-03-01",{"name":108,"class":75},"Xinjiang Medical University"]